103 glucose level
Searched over 200M research papers
Summary
5 papers analyzed
These studies suggest that miR-103 and its variants are involved in insulin resistance and type 2 diabetes, serving as potential biomarkers and therapeutic targets.
Not a yes or no question
To use the Consensus Meter, try asking a simple yes or no question
Research summarized with Copilot
Beta20 papers analyzed
Understanding the Role of miR-103 in Glucose Regulation and Type 2 Diabetes
miR-103 and Glucose Homeostasis
MicroRNA-103 (miR-103) has emerged as a significant player in the regulation of glucose homeostasis, particularly in the context of type 2 diabetes mellitus (DM2). Research indicates that miR-103 influences glucose metabolism by targeting specific genes involved in insulin signaling and glucose regulation .
miR-103 as a Biomarker for Type 2 Diabetes
Several studies have highlighted the potential of miR-103 as a biomarker for the early diagnosis of DM2. For instance, circulating levels of miR-103a and miR-103b have been shown to correlate with glucose metabolism and other DM2 risk factors, making them valuable for predicting the progression from normal glucose tolerance to pre-diabetes and DM2. Additionally, platelet-derived miR-103b has been identified as a novel biomarker for early DM2 diagnosis, as it negatively regulates the expression of secreted frizzled-related protein 4 (SFRP4), a known risk biomarker for pre-diabetes.
miR-103 and Insulin Resistance
miR-103 is also closely linked to insulin resistance, a key feature of DM2. Elevated levels of miR-103 have been associated with increased insulin resistance and nonalcoholic fatty liver disease (NAFLD). This microRNA is positively correlated with markers of insulin resistance such as the homeostasis model assessment of insulin resistance (HOMA-IR), triglycerides (TG), and body mass index (BMI). Furthermore, miR-103 and miR-107 have been shown to regulate insulin sensitivity by targeting caveolin-1, a critical regulator of the insulin receptor. Silencing these microRNAs improves glucose homeostasis and insulin sensitivity, while their overexpression impairs these processes.
Impact of Metformin on miR-103 Levels
Metformin, a common medication for DM2, has been found to modulate the levels of miR-103 and miR-107. In obese type 2 diabetic patients treated with metformin, there is a significant down-regulation of these microRNAs, which correlates with improved insulin sensitivity and glucose metabolism. This suggests that metformin's therapeutic effects may, in part, be mediated through its impact on miR-103 and miR-107 expression.
Conclusion
miR-103 plays a crucial role in glucose regulation and insulin sensitivity, making it a promising biomarker for the early diagnosis and management of type 2 diabetes. Its regulation of key genes involved in insulin signaling underscores its potential as a therapeutic target. Further research into miR-103 could lead to new strategies for diagnosing and treating DM2, ultimately improving patient outcomes.
Sources and full results
Most relevant research papers on this topic
